Industrial Sponsored Research
1. A Phase 3 Randomized, Placebo-Controlled, Double - Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subject with Moderate to Severe Atopic Dermatitis.
2. Multi-centre, double-blind, randomized placebo-controlled, Phase II Study to evaluate efficacy safety and tolerability of a single intravenous dose of BI6556130 in patient with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to severe intensity.